Methylphenidate: a review of its neuropharmacological, neuropsychological and adverse clinical effects.
Leonard
Brian E
BE
Department of Pharmacology, National University of Ireland, Galway, Ireland. belucg@iol.ie
McCartan
Denise
D
White
John
J
King
David J
DJ
D000328:Adult; D000818:Animals; D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy; D001519:Behavior / Q000187:drug effects; D001930:Brain Injuries / Q000188:drug therapy / Q000523:psychology; D000697:Central Nervous System Stimulants / Q000009:adverse effects* / Q000494:pharmacology* / Q000627:therapeutic use; D002648:Child; D003071:Cognition / Q000187:drug effects; D018765:Dopamine Uptake Inhibitors / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D004347:Drug Interactions; D006801:Humans; D008774:Methylphenidate / Q000009:adverse effects* / Q000494:pharmacology* / Q000627:therapeutic use; D009290:Narcolepsy / Q000188:drug therapy; D016032:Randomized Controlled Trials as Topic; D013237:Stereoisomerism; D019966:Substance-Related Disorders / Q000209:etiology
D000697:Central Nervous System Stimulants; D018765:Dopamine Uptake Inhibitors; D008774:Methylphenidate